AUROPHARMA - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.4
| Stock Code | AUROPHARMA | Market Cap | 72,455 Cr. | Current Price | 1,248 ₹ | High / Low | 1,320 ₹ |
| Stock P/E | 33.8 | Book Value | 369 ₹ | Dividend Yield | 0.32 % | ROCE | 10.8 % |
| ROE | 8.65 % | Face Value | 1.00 ₹ | DMA 50 | 1,213 ₹ | DMA 200 | 1,177 ₹ |
| Chg in FII Hold | -0.26 % | Chg in DII Hold | 0.06 % | PAT Qtr | 595 Cr. | PAT Prev Qtr | 581 Cr. |
| RSI | 53.2 | MACD | 26.0 | Volume | 8,45,543 | Avg Vol 1Wk | 12,77,838 |
| Low price | 994 ₹ | High price | 1,320 ₹ | PEG Ratio | 7.92 | Debt to equity | 0.21 |
| 52w Index | 77.8 % | Qtr Profit Var | 26.0 % | EPS | 36.7 ₹ | Industry PE | 27.2 |
📊 Aurobindo Pharma (AUROPHARMA) shows moderate fundamentals. ROCE (10.8%) and ROE (8.65%) are stable but not particularly strong compared to industry leaders. The company has manageable leverage (Debt-to-equity: 0.21) and EPS of 36.7 ₹. However, the stock trades at a P/E of 33.8, higher than the industry average of 27.2, suggesting a premium valuation. The PEG ratio of 7.92 indicates limited growth relative to valuation. Dividend yield is modest at 0.32%. Quarterly profit growth (+26%) is encouraging, showing operational improvement.
💡 Entry Price Zone: Considering RSI (53.2, neutral), MACD (26.0, bullish), and support levels around 1,050–1,150 ₹, the ideal entry zone would be closer to 1,080–1,150 ₹ for long-term investors.
📈 Exit Strategy / Holding Period: If already holding, investors should maintain a medium to long-term horizon (3–5 years). Given the stable ROE/ROCE and improving profits, long-term holding is justified. Partial profit booking can be considered if the stock revisits 1,300–1,320 ₹ levels. Sustained earnings growth will be key to supporting valuations.
Positive
- Quarterly profit growth of 26% (PAT up from 581 Cr. to 595 Cr.).
- EPS of 36.7 ₹ indicates profitability.
- Debt-to-equity ratio of 0.21 shows manageable leverage.
Limitation
- ROCE (10.8%) and ROE (8.65%) are modest compared to peers.
- High P/E (33.8) relative to industry average (27.2).
- PEG ratio (7.92) suggests overvaluation relative to growth.
Company Negative News
- FII holdings reduced by -0.26%, showing slight foreign investor caution.
Company Positive News
- DII holdings increased (+0.06%), reflecting domestic institutional support.
- Consistent profitability with improving quarterly earnings.
Industry
- Pharma industry P/E average: 27.2, highlighting Aurobindo’s premium valuation.
- Sector growth driven by global demand for generics and specialty drugs.
Conclusion
⚖️ Aurobindo Pharma is a fundamentally stable company with improving profitability, but trades at a premium valuation. Long-term investors should wait for a correction toward 1,080–1,150 ₹ before entering. Existing holders can maintain positions with a 3–5 year horizon, but should monitor earnings growth and consider partial exits near 1,300–1,320 ₹ levels. The stock is a cautious long-term hold with moderate growth potential.